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Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk
compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk
is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients
with T2D, so it is paramount to determine the relationship between these two diseases.
Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug
Administration published guidance for manufacturers on antihyperglycemic agents, requiring
studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents
have conducted and published results from CV outcomes trials (CVOTs), with more trials due
to publish soon. This review discusses the relationship between CVD and T2D and explores
findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their
prescribing patterns for patients with T2D.
Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should
be included in prescribing decisions.
Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus,
nurse practitioners
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Prior to the advent of insulin therapy, limited tools were available to prevent the progression of diabetes. As patient survival increased with insulin use, cardiovascular (CV) disease (CVD) management emerged as a key priority in improving patient lives.1 Patients
with type 2 diabetes (T2D) are still at increased CV risk compared to their peers without
diabetes, with some data suggesting that they are at double the risk of CVD compared
to their healthy counterparts.1–3 CVD also remains the leading cause of death in T2D.4,5
A scientific statement from the American Heart Association and the American
Diabetes Association (ADA) explains that for every 18 mg/dL (1 mmol/L) increase
in fasting plasma glucose, the risk of future CV events or death increases by 17%.2 A
rise of 1% (11 mmol/mol) in HbA1c results in an 18% increase in risk of CV events.2
Furthermore, an analysis of eleven large, integrated health care organizations in the
United States found an increased CV risk if HbA1c was ≥9% (75 mmol/mol).6 The
European Prospective Investigation of Cancer and Nutrition (EPIC)-Norfolk study
found that an increase of 1% in HbA1c is associated with a 28% increase in risk of
all-cause death in men, independent of age, blood pressure, serum cholesterol, body
mass index, and cigarette smoking (P<0.002).7
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Data from the UKPDS trial in patients with T2D without
CVD demonstrated a reduction of at least 12% in the risk
of CV complications with every 1% decrease in HbA1c,8 as
well as a reduction in the risk of myocardial infarction (MI)
with intensive vs standard therapy after 10-year observation.9
According to the ADA/European Association for the Study
of Diabetes (EASD) Position Statement 2015, the impact of
glucose control on CV complications remained to be fully
elucidated at that time; a benefit may only emerge after
many years of improved glycemic control.10 Consequently,
the ADA and EASD have recently released a joint consensus
report to aid the decision-making process when prescribing
antidiabetic therapies, with emphasis being placed on the
management of CV risk factors.11
This review will discuss the relationship between CVD
and T2D and examine the findings from the latest CV outcomes trials (CVOTs) of glucose-lowering agents.

Cardiovascular outcomes trials in type 2
diabetes
Historically, new therapies for T2D required evidence for
improving glycemic control from Phase II and III trials.
However, in 2008, after the controversial results from a
meta-analysis of rosiglitazone trials,12 the US Food and
Drug Administration published “Guidance for industry”,
stating that manufacturers of all new antidiabetic therapies
must also demonstrate that the therapy will not result in an
increased risk for CVD.13 Since this guidance was produced,
a number of CVOTs have been conducted, to ensure that
antidiabetic agents do not increase the risk of CV events. In
CVOT design, a glucose-lowering drug is added to standard
of care (SoC) treatments in patients at high risk of CV events
(either patients with advanced diabetes, elderly patients, or
those with renal impairment), and compared with SoC alone
or added to an active comparator. The majority of CVOTs
use a composite primary outcome known as a 3-point
major adverse cardiovascular event (MACE), comprising
CV death, nonfatal MI, and nonfatal stroke. Some also
include hospitalization for heart failure (HF) and/or other
endpoints.13 According to the guidance, CVOTs comparing an antihyperglycemic agent with a comparator must
demonstrate that the upper bound of a two-sided 95% CI
is <1.8.13 Recently, results from these CVOTs have demonstrated that some newer glucose-lowering therapies appear
not only to have no detrimental impact on CV safety but
additionally have beneficial effects on CVD beyond simple
glucose control.14–16
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Review of the cardiovascular safety
profile of medications for type 2 diabetes
All manufacturers of dipeptidyl peptidase 4 inhibitors (DPP4is), sodium–glucose cotransporter-2 inhibitors (SGLT-2is),
and glucagon-like peptide-1 receptor agonists (GLP-1RAs)
have initiated CVOTs, many of which are complete, and there
are a number of other drugs with demonstrable CV safety
(Table 1). Many older drugs do not have published CVOTs, but
some have established CV outcomes from other trials (Table 1).

Metformin, sulfonylureas, thiazolidinediones,
meglitinides, and alpha-glucosidase inhibitors
Metformin remains the mainstay of first-line therapy in
the treatment of T2D17 owing to its efficacy in lowering
glucose, neutral effect on weight, minimal hypoglycemia,
and low cost. Metformin has also been shown to reduce
the risk of CV outcomes, including MI, HF, and stroke.18
Sulfonylureas (SUs) appear to have mixed effects on CV
endpoints. A meta-analysis of randomized controlled trials
with SUs demonstrated no significant effects on MACE or
MI independently, but an association with an increased risk
of stroke and CV death was observed.19 The thiazolidinedione
(TZD) rosiglitazone is associated with an increased risk of
MI and CV mortality.12 Despite later data from the RECORD
trial showing no increased risk in overall CV morbidity
and mortality20 (although it did show an increase in HF),
it is generally well accepted that the initial results from the
meta-analysis are more reliable than RECORD, as this trial
was unblinded.21,22 Conversely, patients treated with another
TZD, pioglitazone, experienced a reduction in the progression of atherosclerosis, significantly reduced plasma lipid
levels compared with rosiglitazone, and decreased apoptosis
induced by ischemic injury, suggesting that the CV effects of
TZDs are not a class effect.23 The CV safety of meglitinides
is yet to be fully elucidated,24 although the NAVIGATOR
study demonstrated similar rates in CV outcomes in patients
treated with nateglinide compared with those treated with
placebo.25 Data are also lacking on the CV safety of alphaglucosidase inhibitors, although the Acarbose Cardiovascular
Evaluation (ACE) trial demonstrated no reduction in MACE
in Chinese patients with impaired glucose tolerance treated
with acarbose.26

The clinical implications of CVOT data for older
antidiabetic therapies
Although metformin has the longest history of CV safety in
antidiabetic therapies, there are no modern CVOTs to assess
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DPP-4 inhibitors
Saxagliptin
Alogliptin
Sitagliptin
Vildagliptin
Linagliptin

Meglitinides
Repaglinide
Nateglinide

Pioglitazone

Increased MI and risk
of CV death
n/a

No, meta-analysis of
clinical trials12
No

SAVOR-TIMI-5328
EXAMINE55
TECOS30
No
CAROLINA
(Clinicaltrials.gov)
CARMELINA32
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Completed; data nyr

Non-inferior vs SoC
Non-inferior vs SoC
Non-inferior vs SoC
n/a
nyc

n/a
n/a

n/a
n/a
n/a
n/a
n/a

No
No
No
No
No

No
No

n/a

NS vs placebo
n/a

n/a

Effects on CV
outcomes

No

ACE26
No

Alpha-glucosidase
inhibitors
Acarbose
Miglitol

Amylin analogues
Pramlinitide
Sulfonylureas
Tolbutamide
Glipizide
Glimepiride
Glibenclamide
Gliclazide
Thiazolidinediones
Rosiglitazone

No

CVOT completed with
the drug in question?

Biguanides
Metformin

Drug

Table 1 Cardiovascular safety with antidiabetic agents

↓CV risk factors

↓ 1.5 kg

Weight-neutral

↑ 1.77 kg when used
with MET

↑2.08 kg when used
with MET

↑2.06 kg when used
with MET

Possible beneficial
cardioprotective effects
Alogliptin and saxagliptin do
not increase risk of major
CV events

Repaglinide ↓inflammation
markers, platelet activation,
lipid parameters

Pioglitazone ↓CV risk,
mortality, MI and stroke

Newer SUs may have ↓CV
risk

GI side effects

↓hypertension
↓CV events
↓T2D development

Weight neutral/↓
1.0 kg

May ↑ischemic events in pts with
severe CAD
No effect on reduced CV outcomes
Less effective than MET in delaying
diabetes or CV onset
↑hospitalization for HF with
saxagliptin

↑CV risk with age and diabetes
duration
Rosiglitazone ↑risk of MI, CHF,
mortality, triglyceride, LDL
cholesterol

GI side effects, hypoglycemia,
headache, weight loss, fatigue
May ↑risk of stroke and CV death
May prevent protective ischemic
cardiac preconditioning after MI

Lactic acidosis (rare)
Caution in older patients with CHF,
renal or hepatic insufficiency

↓CV events
↓BP
↓LDL cholesterol
↑HDL cholesterol

Weight neutral/↓
0.6 kg to 2.9 kg

Key disadvantages

Key advantages

Weight effect

(Continued)

Biguanides
TZDs
DPP-4is
GLP-1RAs
SGLT-2is
Basal insulin
Bigunides
Meglitinides
DPP-4is
GLP-1RAs
SGLT-2is
SUs
Insulin
Biguanides
TZDs
Alpha-glucosidase
inhibitors
Basal insulin
Biguanides
SUs
TZDs
Basal insulin

SUs
Meglitinides
TZDs
DPP-4is
GLP-1RAs
SGLT-2is
Insulin
Biguanides
SUs
Meglitinides
TZDs
Insulin
Prandial insulin

Compatible with
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DEVOTE51

Insulin degludec

No difference vs
SoC
Non-inferior vs
insulin glargine

nyc

Non-inferior vs SoC

Superior vs SoC
Superior vs SoC

Superior vs SoC

Non-inferior vs SoC
Non-inferior vs SoC
Non-inferior vs SoC
Superior vs SoC
Superior vs SoC
Non-inferior vs Soc
Superior vs SoC

Effects on CV
outcomes

↑ 1.6 kg with insulin
glargine
No difference
between insulins
tested

↓2–5 kg

Saxagliptin ↓ 0.4 kg

Weight effect

Limited long-term efficacy and safety
data
Genital tract infections and osmotic
diuresis
Increased risk for amputation with
canagliflozin
Not suitable in patients with renal
failure
Modest increases in weight
Increased risk in hypoglycemia of
glargine vs degludec

↓FPG
Mode of action suits oncedaily injection

GI side-effects
Possible ↑ pancreatitis

Key disadvantages

↓body weight and SBP

↓body weight
Antithrombotic, antiinflammatory, lipid-lowering
effects
↓risk of CVD with exenatide
Superiority in MACE with
lira, sema s.c. and dulaglutide

Key advantages

Biguanides
Alpha-glucosidase
inhibitors
SUs
TZDs
Meglitinides
DPP-4is
GLP-1RAs
SGLT2is

Biguanides
SUs
TZDs
DPP-4is
Insulin

Biguanides
SUs
TZDs
Basal insulin

Compatible with

Notes: Copyright ©2014. Ochsner Journal. Adapted from Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014;14(4):616–632.24 aSUSTAIN 6 was a preapproval trial, and
superiority was demonstrated as a post hoc analysis.
Abbreviations: ACE, Acarbose Cardiovascular Evaluation; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; DPP4i,
dipeptidyl peptidase-4 inhibitor; FPG, fasting plasma glucose; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist; HDL, high-density lipoprotein; HF, heart failure; LDL, low-density lipoprotein; lira, liraglutide; MACE,
major adverse cardiovascular event; MET, metformin; MI, myocardial infarction; n/a, not applicable; NS, not significant; nyc, not yet complete; nyr, not yet reported; SBP, systolic blood pressure; s.c., subcutaneous; sema, semaglutide; SoC,
standard of care; SU, sulfonylurea; TZD, thiazolidinediones.

ORIGIN50

VERTIS CV
(Clinicaltrials.gov)

EMPA-REG
OUTCOME14
CANVAS15 /CREDENCE
(Clinicaltrials.gov)
DECLARE-TIMI-5841

ELIXA47
FREEDOM-CVO56
EXSCEL48
LEADER16
SUSTAIN 6*45
PIONEER 657
HARMONY
Outcomes44
REWIND58

CVOT completed with
the drug in question?

Second-generation
insulin analogs
Insulin glargine

Ertugliflozin

Dapagliflozin

Dulaglutide
SGLT-2 inhibitors
Empagliflozin
Canagliflozin

GLP-1RAs
Lixisenatide
ITCA 650
Exenatide
Liraglutide
Semaglutide s.c.
Semaglutide oral
Albiglutide

Drug

Table 1 (Continued)

Hinnen and Kruger
Dovepress

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12

Dovepress

benefits and safety of metformin on a background of current
SoC for glucose control and other CV risk factors. Treatment
with SUs is associated with weight gain, which remains
a concern in patients with T2D. Moreover, an increased
possibility of CV death and stroke means that prescribers
should probably avoid these agents in patients at high risk
for these events. Furthermore, rosiglitazone has had mixed
CV results,12,20 indicating its use in patients at high risk for
CV events needs to be considered carefully.

Newer therapies for T2D: dipeptidyl peptidase-4
inhibitors (DPP-4is), sodium-glucose cotransporter-2
inhibitors (SGLT-2is), glucagon-like peptide-1
receptor agonists (GLP-1RAs), and secondgeneration insulin analogs
A comprehensive meta-analysis evaluating data from 170 randomized controlled trials comparing the CV effects of novel
antidiabetic medications (including DPP-4is, GLP-1RAs,
and SGLT-2is) with those of traditional classes of drugs
(including insulin, metformin, SU, and TZD) determined
that, in general, newer antidiabetic agents show favorable
CV safety, yet discrepancies exist between individual and
class comparisons.27
To date, all CVOTs of DPP-4is have reported
noninferiority in terms of CV safety with the composite
MACE endpoint when compared with placebo, both on a
background of SoC, thus suggesting no harm.28–30 Results
from a recently published meta-analysis also confirmed a
lack of CV benefit and inferred that DPP-4is are inferior to
SGLT-2is and GLP-1RAs in preventing CV-related death.31
The CAROLINA trial is yet to publish results for the CV
safety of linagliptin (NCT01243424, Clinicaltrials.gov).
However, preliminary findings from the CARMELINA
trial suggest that treatment with linagliptin has no impact
on CV and HF events.32
Notably, some negative individual CV outcomes have
been revealed with specific DPP-4is. Saxagliptin has been
associated with an increased risk for hospitalization for HF.33
While alogliptin was not associated with increased risk of
certain HF outcomes (such as hospital admission for HF)
compared with placebo, hospital admissions for HF occurred
significantly more often in patients without prior history of
HF treated with alogliptin compared with placebo.34
Other DPP-4is have not been associated with an
increased risk of HF. Both linagliptin and sitagliptin do not
appear to increase the risk of HF in patients with diabetes.35
As these results are conflicting with those from saxagliptin
and alogliptin, the HF concerns may not be a class effect,
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and currently, no mechanism for the association between
DPP-4is and HF has been identified.35 It should be noted
that the trial designs and patient population of these trials
are not directly comparable, and therefore these safety differences may be attributable to these other factors rather
than to the drugs.
Findings from two recent meta-analyses of data on
SGLT-2is suggest favorable effects against CV outcomes
and death.36,37 These reflect that the CVOT data for SGLT-2is
empagliflozin and canagliflozin have demonstrated superiority of the trial drug in MACE outcomes when compared
with SoC, suggesting a cardioprotective effect of these
agents.14,15 Data from the EMPA-REG OUTCOME trial with
empagliflozin led to an update in the label, and the therapy
is now indicated to reduce the risk of CV death in patients
with T2D and established CVD.38 This decision has since
been validated by the ADA and EASD.11,39,40 The DECLARETIMI 58 Phase III CVOT with dapagliflozin demonstrated
noninferiority, but not superiority, for MACE.41 When the
components of this composite endpoint were analyzed, it was
shown that dapagliflozin significantly reduced the number of
hospitalizations for HF.41 It seems unlikely therefore that the
CV benefits associated with empagliflozin and canagliflozin
are a class effect, but perhaps there is a class effect for HF.
It is also unknown if empagliflozin, canagliflozin, or other
SGLT-2is will have similar effects in patients with T2D but
at low CV risk.40
Data from further CVOTs with ertugliflozin and sotagliflozin may help to elucidate if any SGLT-2i class effect
exists (NCT01986881 and NCT03521934, respectively,
Clinicaltrials.gov). The current ongoing VERTIS CV study
assesses ertugliflozin in patients with T2D and established
vascular disease, and the SOLOIST-WHF trial assesses
sotagliflozin in patients with T2D with worsening HF. It
will still be some time before the long-term safety and realworld impact of SGLT-2is in patients with T2D with HF/
CVD become clear.
Meta-analyses of CVOT data on GLP-1RAs suggest cardioprotective effects in patients with high CV risk.42,43 A CV
benefit was demonstrated in both the LEADER trial and the
HARMONY Outcomes trial for the GLP-1RAs liraglutide
and albiglutide, respectively, when compared with SoC.16,44
Also, even though testing for superiority of the primary composite endpoint was not prespecfied in SUSTAIN 6, a post hoc
analysis of its data suggests that the once-weekly subcutaneous GLP-1RA, semaglutide, may also offer a CV benefit.45
In the LEADER trial, significantly fewer patients treated
with liraglutide experienced MACE, compared with those
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treated with placebo, a statistically superior result.16 This led
to an update in the label, and liraglutide is now indicated to
reduce the risk of MACE in patients with T2D and established
CVD,46 which is also reflected in the new consensus report
from the ADA/EASD.11 The SUSTAIN 6 trial demonstrated
noninferiority of subcutaneous semaglutide to placebo for
MACE, and a post hoc analysis also showed superior CV
benefit for patients treated with semaglutide compared with
those treated with placebo. Testing for superiority was not
prespecified or adjusted for multiplicity.45 In the HARMONY
Outcomes trial, albiglutide therapy was found to be superior
to placebo with respect to MACE and resulted in a significant
reduction in MIs (it is important to note that albiglutide is no
longer commercially available).44
In comparison, lixisenatide and once-weekly exenatide
have only demonstrated noninferiority compared with placebo.47,48 Study investigators in the EXSCEL trial with onceweekly exenatide suggested that the disproportionate use of
diabetes therapies known to reduce CV risk in the placebo
group, such as SGLT-2is and other GLP-1RAs, may have preferentially resulted in lower event rates in the placebo arm.48
Whether there is a GLP-1RA class effect in CV safety
remains to be determined, but appears unlikely given the
results obtained thus far in CVOTs. As yet, the mechanism
underlying the emerging cardioprotective effect of GLP1RAs has not been identified and it is unknown whether this
effect occurs via GLP-1, its receptor, or other pathways.49 The
mixed results seen in CVOTs of GLP-1RAs may be attributed
to varying molecular structures, as human analogs appear to
perform better than the exendins, which are larger than, and
molecularly different to, the human analogs. Further clarity
will be available after the results from REWIND with dulaglutide and PIONEER 6 with oral semaglutide are published
in full (NCT01394952 and NCT02692716, respectively;
Clinicaltrials.gov).
Only two basal insulins have been investigated in CVOTs.
Trials with insulin glargine (U100 Lantus) demonstrated no
significant difference in MACE compared with SoC in the
ORIGIN trial,50 and the DEVOTE trial revealed noninferiority of insulin degludec compared with insulin glargine in
MACE.51

Dovepress

Newer agents DPP-4is, GLP-1RAs, and SGLT-2is have
the most data on CV effects. As DPP-4is do not appear
to improve CV outcomes compared with controls, it is
unlikely that they will be used to reduce CV benefits.

Although, real-world data have demonstrated that the
benefits seen with empagliflozin in CVOTs are applicable
to a broad population of patients with T2D in clinical
practice,52 it is uncertain how trial outcomes for other
SGLT-2is will translate into the real-world setting. Additionally, safety evidence is lacking in specific populations,
such as the very elderly population.
The GLP-1RAs liraglutide and semaglutide have
also demonstrated a benefit in CV outcomes,16,45 which
supports their use in patients at high risk of CV events.
This fact has been highlighted by the ADA/EASD, who
have given preference to the use of liraglutide, based on
the LEADER trial, and empagliflozin, based on EMPAREG OUTCOME, in this patient population.11 Further
information on the long-term effects of these agents and
the mechanisms behind their functions will become available with the arrival of results from ongoing and future
CVOTs with GLP-1RA and SGLT-2is. Going forward,
some investigators are exploring the potential to broaden
the use of newer antidiabetic therapies beyond that of T2D.
The Phase III EMPEROR-Preserved and EMPERORReduced trials investigating empagliflozin in patients
with chronic HF are presently ongoing (NCT03057951
and NCT03057977, respectively; Clinicaltrials.gov) and,
once published, will offer insight into the potential nondiabetic use of these agents.
Both insulin glargine and insulin degludec are associated
with no increased risk of CV events compared with SoC.50,51
However, weight gain and hypoglycemia remain a concern
with insulin,53 and therefore other injectable therapies may
be more appropriate prior to initiating insulin regimens.
This is reflected in the ADA/EASD 2018 consensus report,
wherein GLP-1RAs are generally recommended as the first
injectable therapy.11
CV events are not the only adverse events collected
for analysis during CVOTs. On occasion, some of these
other events may indicate an unexpected safety signal. For
example, in CANVAS, it was determined that there was a
twofold increase in the number of lower-extremity amputations reported with canagliflozin therapy.15 This resulted in
a boxed warning about the risk of lower limb amputation on
the prescribing information leaflet.54 Also, SGLT-2is increase
the risk of genital infections.14,15,38,54 These other adverse
events indicate the need for nurse practitioners to be aware
of all data reported from such studies and to discuss carefully
risks and benefits with patients. Further clinical evaluation
and documentation of vascular status and sensation with
thorough foot exams are prudent as well.
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Conclusion
CV benefits are typically observed alongside glycemic efficacy even with older treatments, such as metformin, although
no CVOTs for these treatments have been completed. Having
effective glucose-lowering agents that also demonstrate multifaceted benefits such as CVD risk reduction has profound
implications for the development of new agents that will, by
necessity, have to be compared with strategies of care that
include SGLT-2is and GLP-1RAs. Nurse practitioners have
data to support making informed decisions based on the CV
effects of different therapies and individual patient risk factors when prescribing.
For patients with T2D who are at particularly high risk
for CV events, the CV risks and benefits of antidiabetic
drugs should inform prescribing decisions. Currently,
only empagliflozin and liraglutide are licenced for use in
patients with T2D and CVD, and these therapies should be
prioritized when considering treatment for patients with
comorbid CVD.
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